Labcorp Evolves Its Brand to Showcase Its Role as a Trusted Source in Healthcare

<span>Roche receives FDA Emergency Use Authorization for new semi-quantitative test to measure the level of SARS-CoV-2 antibodies</span>
December 1, 2020

Roche receives FDA Emergency Use Authorization for new semi-quantitative test to measure the level of SARS-CoV-2 antibodies

INDIANAPOLIS, Dec. 1, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced that its Elecsys® Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The semi-quantitative serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus.

CancerIQ Officially Launches Lab Network to Increase Awareness and Accelerate Adoption of Genetic Testing

Labcorp Is Scheduled to Present at The 2020 Evercore ISI 3rd Annual HealthCONx Conference